A 23-year-old woman with bilateral blurry vision, floaters, and a history of premature birth presented with exudative retinopathy and vascular features overlapping multiple inherited and acquired retinal disorders.

Two retina specialists debated whether LIGHTSITE III evidence supports photobiomodulation as treatment for intermediate dry AMD, weighing modest BCVA gains against natural visual acuity variability, study quality concerns, and FDA authorization status.

Bayer agreed to acquire Perfuse Therapeutics in a deal valued at up to $2.45 billion, gaining full rights to a phase 2 endothelin receptor antagonist for glaucoma and diabetic retinopathy.

The American Academy of Ophthalmology updated hydroxychloroquine retinopathy screening recommendations, emphasizing dose limits, OCT and FAF as primary screening modalities, and risk stratification by renal status and concurrent tamoxifen use.

A phase 3 head-to-head RCT of 689 patients found intravitreal brolucizumab preserved visual acuity at 54 weeks while panretinal photocoagulation patients lost a mean of approximately 4 letters, though intraocular inflammation rates were higher with brolucizumab.

The critical care nurse has a significant role to play in facilitating timely interventions for intracerebral hemorrhage patients, particularly regarding neurologic status changes and blood pressure control.